Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Dulaglutide vs Empagliflozin: Dulaglutide has the stronger overall evidence (7 vs 4.5/10); they're alternatives for manage blood sugar — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Dulaglutide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Dulaglutide and Empagliflozin have evidence — compare verdict strength side-by-side.
Prescription-only, clinician-prescribed. Subcutaneous 0.75 mg once weekly to start, usually escalated to 1.5 mg; 3.0 mg and 4.5 mg once-weekly doses are available for additional glycemic lowering. DO NOT self-dose.
any
Subcutaneous once-weekly pen (Trulicity)
Off-label use mirrors approved dosing (10–25 mg once daily in the morning) under a clinician. A prescription drug; not an approved longevity regimen.
morning
Oral tablet (empagliflozin)
Weeks to months
Months to years
Months
Especially during initiation/escalation
Months to years
Months to years
Weeks to months
Throughout use
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Lancet (2019) · Rct · n=9901
Multicentre, double-blind, placebo-controlled cardiovascular-outcomes RCT: 9,901 patients aged ≥50 with type 2 diabetes, randomized to subcutaneous dulaglutide 1.5 mg/week or placebo at 371 sites in 24 countries
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Lancet Diabetes Endocrinol (2019) · Meta analysis
Meta-analysis of seven GLP-1 receptor agonist cardiovascular-outcomes trials (ELIXA, LEADER, SUSTAIN-6, EXSCEL, Harmony Outcomes, REWIND, PIONEER 6); 56,004 participants
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Lancet (2019) · Rct · n=9901
Pre-specified exploratory analysis of the REWIND trial (9,901 participants) examining the renal component of the composite microvascular outcome
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The New England journal of medicine (2015) · Rct · n=7020
EMPA-REG OUTCOME randomized trial in high-CV-risk type-2 diabetics
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Circulation (2018) · Rct
Randomized evidence of empagliflozin benefit in established cardiovascular disease
Empagliflozin in Patients with Chronic Kidney Disease.
The New England journal of medicine (2023) · Rct
EMPA-KIDNEY randomized trial in a broad chronic-kidney-disease population
Dulaglutide has a higher evidence score (7/10 vs 4.5/10) and wins in 2 of 3 categories.
For manage blood sugar, Dulaglutide has a higher relevance score (82 vs 62).
No known interactions between Dulaglutide and Empagliflozin have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.